🚀 VC round data is live in beta, check it out!
Corestemchemon Valuation Multiples
Discover revenue and EBITDA valuation multiples for Corestemchemon and similar public comparables like Adicet Bio, Annovis Bio, MediciNova, XBiotech and more.
Corestemchemon Overview
About Corestemchemon
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
Founded
2003
HQ
Employees
326
Website
Sectors
Financials (FY)
EV
$101M
Corestemchemon Financials
Corestemchemon reported last fiscal year revenue of $13M and negative EBITDA of ($14M).
In the same fiscal year, Corestemchemon generated ($3M) in gross profit, ($14M) in EBITDA losses, and had net loss of ($18M).
Corestemchemon P&L
In the most recent fiscal year, Corestemchemon reported revenue of $13M and EBITDA of ($14M).
Corestemchemon expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $13M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($3M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (20%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($14M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (104%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (105%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($18M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (133%) | XXX | XXX | XXX |
| Net Debt | — | — | $24M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Corestemchemon Stock Performance
Corestemchemon has current market cap of $70M, and enterprise value of $101M.
Market Cap Evolution
Corestemchemon's stock price is $2.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $101M | $70M | 0.1% | XXX | XXX | XXX | $-0.63 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCorestemchemon Valuation Multiples
Corestemchemon trades at 7.6x EV/Revenue multiple, and (7.3x) EV/EBITDA.
Corestemchemon Financial Valuation Multiples
As of April 6, 2026, Corestemchemon has market cap of $70M and EV of $101M.
Equity research analysts estimate Corestemchemon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Corestemchemon has a P/E ratio of (3.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $70M | XXX | $70M | XXX | XXX | XXX |
| EV (current) | $101M | XXX | $101M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 7.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (7.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (7.2x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (37.5x) | XXX | XXX | XXX |
| P/E | — | XXX | (3.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Corestemchemon Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Corestemchemon Margins & Growth Rates
Corestemchemon's revenue in the last fiscal year declined by (30%).
Corestemchemon's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
Corestemchemon Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (30%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (104%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (5%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 85% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Corestemchemon Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Adicet Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Annovis Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| MediciNova | XXX | XXX | XXX | XXX | XXX | XXX |
| XBiotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Fractyl Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corestemchemon M&A Activity
Corestemchemon acquired XXX companies to date.
Last acquisition by Corestemchemon was on XXXXXXXX, XXXXX. Corestemchemon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Corestemchemon
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCorestemchemon Investment Activity
Corestemchemon invested in XXX companies to date.
Corestemchemon made its latest investment on XXXXXXXX, XXXXX. Corestemchemon invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Corestemchemon
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Corestemchemon
| When was Corestemchemon founded? | Corestemchemon was founded in 2003. |
| Where is Corestemchemon headquartered? | Corestemchemon is headquartered in South Korea. |
| How many employees does Corestemchemon have? | As of today, Corestemchemon has over 326 employees. |
| Is Corestemchemon publicly listed? | Yes, Corestemchemon is a public company listed on Korea Exchange. |
| What is the stock symbol of Corestemchemon? | Corestemchemon trades under 166480 ticker. |
| When did Corestemchemon go public? | Corestemchemon went public in 2015. |
| Who are competitors of Corestemchemon? | Corestemchemon main competitors are Adicet Bio, Annovis Bio, MediciNova, XBiotech. |
| What is the current market cap of Corestemchemon? | Corestemchemon's current market cap is $70M. |
| What is the current revenue of Corestemchemon? | Corestemchemon's last fiscal year revenue is $13M. |
| What is the current EV/Revenue multiple of Corestemchemon? | Current revenue multiple of Corestemchemon is 7.6x. |
| Is Corestemchemon profitable? | No, Corestemchemon is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.